Melatonin Supplementation for Delirium Prevention in Acutely Hospitalized Elderly

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's122 enrolled

Overview

122 people over 70 who were admitted to hospital were enrolled to the study. Half got .5 mg a night of melatonin, half got a placebo.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

122

Conditions

Delirium

Interventions

melatoninDIETARY_SUPPLEMENT

one half of a 1 mg tablet of GNC rapid dissolving Melatonin, NPN (natural product number) 80001380, available over the counter in Canada

placeboDIETARY_SUPPLEMENT

half a white placebo tablet

Eligibility

Sex: ALLMin age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age over 65 admitted through the emergency department to an internal medicine service in London, Ontario, Canada. Exclusion Criteria: * Life expectancy less than 24 hours, * Unable to communicate in English, * Unable to take oral medications, * Intracranial bleed or known seizure disorder, * Markedly sub or supra-therapeutic INR while on warfarin, OR * A known allergy to study tablet ingredients.

Locations (1)

London Health Sciences Centre

London, Ontario, Canada

Outcomes

Primary Outcomes

delirious using confusion assessment method (CAM)

Time frame: days

Secondary Outcomes

MDAS (memorial delirium assessment scale)

Time frame: days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.